Skip to main content

Advertisement

SpringerLink
Log in

Against

  • Controversies
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Armitage JO, Mauch PM, Harris NL, Bierman P. Non- Hodgkin’s lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principle and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:2256–2316.

    Google Scholar 

  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242.

    Article  CAS  PubMed  Google Scholar 

  3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333:1540–1545.

    Article  CAS  PubMed  Google Scholar 

  4. Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol 2000; 11 Suppl 1:23–27.

    Article  PubMed  Google Scholar 

  5. Zinzani PL, on behalf of an Italian Cooperative Study Group on Lymphoma. A randomized trial of fludarabine andmitoxantrone plus rituximab versus CHOP plus rituximab as firstline treatment in patients with follicular lymphoma [abstract]. Blood 2001; 98:842a.

    Article  Google Scholar 

  6. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo- Lopez AJ, Bernstein SH. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29 (1 Suppl 2):36–40.

    Article  CAS  PubMed  Google Scholar 

  7. Rohatiner A. Follicle centre cell lymphoma: optimal use of therapeutic options. Ann Oncol 2000; 11 Suppl 3:111–115.

    PubMed  Google Scholar 

  8. Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2000; 11 Suppl 1:91–94.

    Article  PubMed  Google Scholar 

  9. Ostermann H, Hiddemann W. High-dose chemotherapy with stem cell transplantation. Dtsch Med Wochenschr 1999; 124:1397.

    Article  CAS  PubMed  Google Scholar 

  10. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864–869.

    CAS  PubMed  Google Scholar 

  11. Brugger W, Hirsch J, Repp R, Schlimok G, Grunebach F, Vogel W, Kopp HG, Aulitzky W, Ganser A, Gramatzki M, Fehnle K, Kanz L. Treatment of follicular and mantle cell lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem cell transplantation [abstract]. Blood 2000; 96:482a.

    Google Scholar 

  12. Horwitz SM; Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Stuart MJ, Breslin S, Blume KG, Horning SJ. Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin’s lymphomas [abstract]. Blood 2001; 98:862a.

    Google Scholar 

  13. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219–1222.

    Article  CAS  PubMed  Google Scholar 

  14. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336–340.

    Article  CAS  PubMed  Google Scholar 

  15. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270–3278.

    CAS  PubMed  Google Scholar 

  16. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934–2942.

    CAS  PubMed  Google Scholar 

  17. Hiddemann W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16:1922–1930.

    CAS  PubMed  Google Scholar 

  18. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158–3166.

    Article  CAS  PubMed  Google Scholar 

  19. Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, Parwaresch R, Kneba M, Schmitz N, Haas R. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1:87–94.

    Article  CAS  PubMed  Google Scholar 

  20. Gianni AM, Cortelazzo S, Magni M, Martelli M. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transpl 2002; 29 Suppl 1:S10–S13.

    Article  Google Scholar 

  21. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17:3793–3803.

    CAS  PubMed  Google Scholar 

  22. Wahl R, Kaminski R, Zelenetz A, Vose J, Press O, Goldsmith S, Fehrenbacher L, Clapp KJ, Fisher R. Each subsequent therapy results in diminished response rate and duration of response in low grade or transformed low grade non-Hodgkin’s lymphoma [abstract]. J Clin Oncol 2001; 20 (Proc ASCO):292a.

    Google Scholar 

  23. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J. Pretargeted radioimmunotherapy (PRIT) for treatment of non- Hodgkin’s lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15:15–29.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Klinikum r. d. Isar der TUM, Ismaninger Strasse 22, 81675, München, Germany

    Christoph von Schilling

Authors
  1. Christoph von Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Schilling, C. Against. Eur J Nucl Med 29, 1254–1256 (2002). https://doi.org/10.1007/s00259-002-0929-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-002-0929-8

Keywords

Search

Navigation